Evidence map›Paper›PMID 32091594›Full record

Trial reportJournal of the National Cancer Institute2020

Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial.

Aimée R Kreimer, Joshua N Sampson, Carolina Porras, John T Schiller, Troy Kemp, Rolando Herrero, Sarah Wagner, Joseph Boland, John Schussler, Douglas R Lowy and 12 more

Open access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
118citing papers in PubMed, 6 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

118 citing papers in PubMed, 6 syntheses or guidelines pooled it, 199 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Immunogenicity and safety of anFrontiers in immunology · 2025
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Long-Term immunopersistence and safety of theHuman vaccines & immunotherapeutics · 2022
    Trial
  19. Trial
  20. Trial

58 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 3 countries.

Aimée R KreimerNational Cancer Institute, NIH, Bethesda, MD, USA.
Joshua N SampsonNational Cancer Institute, NIH, Bethesda, MD, USA.
Carolina PorrasAgencia Costarricense de Investigaciones Biomédicas (ACIB), Formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
John T SchillerNational Cancer Institute, NIH, Bethesda, MD, USA.
Troy KempHPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Rolando HerreroEarly Detection and Prevention Section, International Agency for Research on Cancer, Lyon, France.
Sarah WagnerNational Cancer Institute, NIH, Bethesda, MD, USA.
Joseph BolandNational Cancer Institute, NIH, Bethesda, MD, USA.
John SchusslerInformation Management Systems, Silver Spring, MD, USA.
Douglas R LowyNational Cancer Institute, NIH, Bethesda, MD, USA.
Stephen ChanockNational Cancer Institute, NIH, Bethesda, MD, USA.
David RobersonNational Cancer Institute, NIH, Bethesda, MD, USA.
Mónica S SierraNational Cancer Institute, NIH, Bethesda, MD, USA.
Sabrina H TsangNational Cancer Institute, NIH, Bethesda, MD, USA.
Mark SchiffmanNational Cancer Institute, NIH, Bethesda, MD, USA.
Ana Cecilia RodriguezIndependent Consultant, San José, Costa Rica.
Bernal CortesAgencia Costarricense de Investigaciones Biomédicas (ACIB), Formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Mitchell H GailNational Cancer Institute, NIH, Bethesda, MD, USA.
Allan HildesheimNational Cancer Institute, NIH, Bethesda, MD, USA.
Paula GonzalezAgencia Costarricense de Investigaciones Biomédicas (ACIB), Formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica.
Ligia A PintoHPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Costa Rica HPV Vaccine Trial (CVT) Group
National Cancer Institute · USInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRFrederick National Laboratory for Cancer Research · USCentre International de Recherche sur le Cancer · FRInformation Management Services · US

Funding

Understanding Papillomavirus Virion Proteins and VaccinesZIABC009052 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SCHILLER, JOHN T. · 2009 to 2025
$38.4M
Papillomavirus Virion Proteins and VaccinesZIABC010579 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LOWY, DOUGLAS R. · 2009 to 2025
$15.4M
NCI NIH HHS N01 CP011005World Health Organization 001
6 · The paper itself

Abstract

backgroundThe authors investigated the durability of vaccine efficacy (VE) against human papillomavirus (HPV)16 or 18 infections and antibody response among nonrandomly assigned women who received a single dose of the bivalent HPV vaccine compared with women who received multiple doses and unvaccinated women.

methodsHPV infections were compared between HPV16 or 18-vaccinated women aged 18 to 25 years who received one (N = 112), two (N = 62), or three (N = 1365) doses, and age- and geography-matched unvaccinated women (N = 1783) in the long-term follow-up of the Costa Rica HPV Vaccine Trial. Cervical HPV infections were measured at two study visits, approximately 9 and 11 years after initial HPV vaccination, using National Cancer Institute next-generation sequencing TypeSeq1 assay. VE and 95% confidence intervals (CIs) were estimated. HPV16 or 18 antibody levels were measured in all one- and two-dose women, and a subset of three-dose women, using a virus-like particle-based enzyme-linked immunosorbent assay (n = 448).

resultsMedian follow-up for the HPV-vaccinated group was 11.3 years (interquartile range = 10.9-11.7 years) and did not vary by dose group. VE against prevalent HPV16 or 18 infection was 80.2% (95% CI = 70.7% to 87.0%) among three-dose, 83.8% (95% CI = 19.5% to 99.2%) among two-dose, and 82.1% (95% CI = 40.2% to 97.0%) among single-dose women. HPV16 or 18 antibody levels did not qualitatively decline between years four and 11 regardless of the number of doses given, although one-dose titers continue to be statistically significantly lower compared with two- and three-dose titers.

conclusionMore than a decade after HPV vaccination, single-dose VE against HPV16 or 18 infection remained high and HPV16 or 18 antibodies remained stable. A single dose of bivalent HPV vaccine may induce sufficiently durable protection that obviates the need for more doses.

Indexed as

AdolescentAdultAntibodies, ViralCosta RicaFemaleHuman papillomavirus 16Human papillomavirus 18HumansPapillomavirus InfectionsPapillomavirus VaccinesVaccines, CombinedYoung AdultAntibodies, ViralPapillomavirus VaccinesVaccines, Combined

Identifiers

PMID32091594
PMCPMC7566548
OpenAlexW3008661842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.